文献速递胸部肿瘤

可切除非小细胞肺癌术前纳武利尤单抗联合或不联合瑞拉利单抗的长期结局(NEOpredict-Lung)

Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).
PubMed 文献 · Eur J Cancer · 2025-12-05

NEOpredict-Lung 研究将 60 例可切除 NSCLC(IB-IIIA 期)患者随机分配接受两剂纳武利尤单抗(240 mg)联合或不联合瑞拉利单抗(80 mg),每 2 周一次。中位随访 37.4 个月时,A 组和 B 组的 3 年 OS 分别为 88.4% 和 88.9%,DFS 分别为 73.3% 和 60.3%;主要病理缓解患者 DFS 有获益趋势(HR 0.35;95%CI 0.1-1.19)。

要点

  • 短程术前纳武利尤单抗联合或不联合瑞拉利单抗显示出令人鼓舞的疗效和生存结局。
  • A 组和 B 组 3 年 OS 分别为 88.4% 和 88.9%,DFS 分别为 73.3% 和 60.3%。
  • 主要病理缓解患者 DFS 有获益趋势(HR 0.35;95%CI 0.1-1.19)。

核心结论

  • 短程术前纳武利尤单抗联合或不联合瑞拉利单抗显示出令人鼓舞的疗效和生存结局,与基于化疗-免疫的围手术期治疗方案相比具有优势。

研究设计与样本

  • NEOpredict-Lung(NCT04205552)随机研究,纳入 60 例可切除 NSCLC(IB-IIIA 期)患者,随机接受两剂纳武利尤单抗(240 mg)联合或不联合瑞拉利单抗(80 mg),每 2 周一次。

主要发现

  • 中位随访 37.4 个月时,45 例患者无病存活,15 例复发(4 例局部区域复发,11 例转移),7 例死亡。
  • A 组和 B 组的 3 年 OS 分别为 88.4% 和 88.9%,3 年 DFS 分别为 73.3% 和 60.3%。
  • 达到主要病理缓解(切除 NSCLC 中存活肿瘤细胞≤10%)的患者 DFS 有获益趋势(HR 0.35;95%CI 0.1-1.19)。
  • A 组和 B 组分别有 53.3% 和 66.7% 的患者确认降期;有淋巴结病变的患者中,A 组和 B 组分别有 28.6% 和 66.7% 发生淋巴结降期。

临床怎么用

  • 可切除 NSCLC 患者可考虑短程术前纳武利尤单抗联合或不联合瑞拉利单抗的新辅助免疫治疗。
  • 主要病理缓解(≤10% 存活肿瘤细胞)与 DFS 获益趋势相关,可作为疗效评估指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative immunotherapy targeting PD-1/-L1 with chemotherapy induces histopathological responses and improves survival in patients with resectable non-small cell lung cancer (NSCLC). NEOpredict-Lung (NCT04205552) established the feasibility of dual blockade of PD-1 and LAG-3 immune checkpoints prior to curatively intended resection. Here we report extended follow-up, postoperative treatments and patterns of response and recurrence. PATIENTS AND METHODS: Patients with resectable NSCLC (stages IB-IIIA) were randomized to receive two doses nivolumab (240 mg, arm A) with or without relatlimab (80 mg, arm B) every 2 weeks. Overall and disease-free survival (OS, DFS) rates, response and recurrence patterns and subsequent therapies were evaluated. RESULTS: 60 patients were enrolled from March 2020 to July 2022. The present analysis was conducted per December 2024 with a median follow-up of 37.4 months. 45 patients were alive without disease recurrence,15 patients recurred (4 locoregional and 11 metastatic), and 7 patients died. The 3-year OS and DFS rates were 88.4 % and 73.3 % in arm A and 88.9 % and 60.3 % in arm B. Patients achieving major pathological response (≤10 % viable tumor cells in resected NSCLC) trended towards better DFS (HR 0.35; 95 % CI, 0.1-1.19). Downstaging was confirmed in 53.3 % of patients in arm A and in 66.7 % of patients in arm B. Nodal downstaging occurred in 28.6 % of patients with nodal disease in arm A and in 66.7 % of patients in arm B. CONCLUSIONS: Short course preoperative nivolumab with or without relatlimab showed encouraging efficacy and survival outcomes, which compare favorably with chemo-immunotherapy-based perioperative treatment regimens.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cuppens K, Wiesweg M, Baas P, et al. Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung). Eur J Cancer. 2025. PMID: 41389771. doi:10.1016/j.ejca.2025.116165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。